AI's hype vs. reality: High valuations meet growing workplace blunders. Is it AS, not AI?
Novo's Wegovy pill hits 3M scripts, dominating GLP-1 market. Lilly eyes Medicare, boosting obesity drug valuations.
Bitcoin, S&P 500 face downside risk; prediction markets show traders expect volatility, not collapse.
Assisted living's $7k/mo cost too steep; traders eye affordable housing ETFs for value.
J&J drops $1B for Firefly Bio's DAC tech, boosting its oncology pipeline and entering the KRAS race.
Broadcom's AI forecast disappoints, sparking a $300B drop. Marvell vs. Broadcom: a post-sell-off play?
Intel jumps 10% as Google taps it for 3M chips. Nvidia also considers Intel, boosting valuation.
Sponsored
Must Read